Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Vanda Pharmaceuticals Inc.    VNDA

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/29/2016 11/30/2016 12/01/2016 12/02/2016 12/05/2016 Date
16.8(c) 16.45(c) 15.5(c) 15.6(c) 15.6(c) Last
884 024 892 620 901 293 383 594 426 235 Volume
-1.75% -2.08% -5.78% +0.65% 0.00% Change
More quotes
Financials ($)
Sales 2016 148 M
EBIT 2016 -20,1 M
Net income 2016 -19,8 M
Debt 2016 -
Yield 2016 -
Sales 2017 185 M
EBIT 2017 -1,60 M
Net income 2017 1,92 M
Debt 2017 -
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017 390,00
Capi. / Sales2016 4,65x
Capi. / Sales2017 3,71x
Capitalization 686 M
More Financials
Company
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders.Its products portfolio includes HETLIOZ, Fanapt and Tradipitant, Trichostatin and AQW051.Vanda Pharmaceuticals was founded by... 
More about the company
Surperformance© ratings of Vanda Pharmaceuticals Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on VANDA PHARMACEUTICALS INC.
11/22 VANDA PHARMACEUTICALS : Announces Participation at November 2016 Investor Confer..
11/17 VANDA PHARMACEUTICALS : Investigators from Vanda Pharmaceuticals Release New Dat..
11/14 VANDA PHARMACEUTICALS : Announces Participation at November 2016 Investor Confer..
11/08 VANDA PHARMACEUTICALS : Research Reports Coverage on Biotech Stocks -- Illumina,..
11/03 VANDA PHARMACEUTICALS : Settles Fanapt® Patent Litigation with Taro
11/03 VANDA PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condit..
11/02 VANDA PHARMACEUTICALS : reports 3Q loss
11/02 VANDA PHARMACEUTICALS INC. : Results of Operations and Financial Condition, Fina..
11/02 VANDA PHARMACEUTICALS : Reports Third Quarter 2016 Financial Results
10/25 VANDA PHARMACEUTICALS INC. (NASDAQ : VNDA) Files An 8-K
More news
Sector news : Bio Therapeutic Drugs
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
11/30 ACTELION : Rejecting J&J could leave Actelion with 'lot of explaining to do'
11/28 Actelion's ambitious independent-minded CEO will drive up takeover price
11/26DJWHAT'S NEWS : Business & Finance -- WSJ
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
11/28 VANDA : Valued Like A Plain Pharma Company, But Isn't One
11/19 Tracking John Paulson's Paulson & Company Portfolio - Q3 2016 Update
11/11 Healthcare ratings roundup - new coverage
11/04 BIOTECH FORUM DAILY DIGEST : DOJ Piles On Biopharma, Investment Case For Gilead ..
11/02 Vanda Pharmaceuticals' (VNDA) CEO Mihael Polymeropoulos on Q3 2016 Results - ..
Advertisement
Chart VANDA PHARMACEUTICALS INC.
Duration : Period :
Vanda Pharmaceuticals Inc. Technical Analysis Chart | VNDA | US9216591084 | 4-Traders
Full-screen chart
Technical analysis trends VANDA PHARMACEUTI...
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 22,5 $
Spread / Average Target 44%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Mihael Hristos Polymeropoulos President, Chief Executive Officer & Director
H. Thomas Watkins Chairman
James Patrick Kelly Chief Financial Officer, Treasurer & Senior VP
Paolo Baroldi Chief Medical Officer & Senior Vice President
Howard H. Pien Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
VANDA PHARMACEUTICALS ..67.56%686
AMGEN, INC.-11.29%107 132
GILEAD SCIENCES, INC.-28.02%95 410
CELGENE CORPORATION-1.78%91 187
REGENERON PHARMACEUTIC..-31.34%39 310
ACTELION LTD40.40%21 739
More Results